August 13, 2021 09:52 AM EDTUpdated 11:57 AM
Peer Review

Robert Baze­more makes Hutchmed deal his grand fi­nale as Epizyme CEO; Black Di­a­mond reshuf­fles the deck with de­par­tures of CMO, CSO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Paul Schloesser

Associate Editor

→ One minute, Epizyme CEO Robert Baze­more helped en­gi­neer a part­ner­ship with Hutchmed on de­vel­op­ing Tazverik in Chi­na. The next minute, he gave his job …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

It's been three months with­out a biotech IPO

A service from the Financial Times